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A B S T R A C T
Background: Anxiety disorders occur in up to 35% of patients with Parkinson's disease (PD) and have a negative
effect on motor symptoms and quality of life. To date, no clinical trials specifically targeting anxiety in PD
patients have been published.
Objective: To describe the rationale and methodology of a randomised controlled trial (RCT) that aims to study
the clinical effectiveness, alterations in brain circuitry, and cost-effectiveness of cognitive behavioural therapy
(CBT) for anxiety in PD.
Methods: This study is a prospective, two-centre RCT in which sixty PD patients with anxiety will be randomised
to CBT treatment and clinical monitoring (intervention group) or to clinical monitoring only (control group). The
CBT module used in this study was specifically developed to address symptoms of anxiety in PD patients.
Participants will undergo standardised clinical, cognitive and behavioural assessment at baseline and at 2 follow-
up measurements, as well as resting-state fMRI and DTI scanning before and after the intervention. The primary
outcome measure is changes in severity of anxiety symptoms. Secondary outcome measures involve long-term
changes in anxiety symptoms, changes in functional and structural connectivity between limbic and frontal
cortices, and cost-effectiveness of the treatment. The study is registered at the ClinicalTrials.gov database under
registration number NCT02648737.
Conclusion: This study is the first that evaluates both the clinical effectiveness, cost-effectiveness, as well as the
biological impact of CBT for anxiety in PD patients that, if proven effective, will hopefully contribute to a better
and evidence-based approach for these non-motor symptoms.
1. Background
Anxiety disorders occur in up to 35% of patients with Parkinson's
disease (PD) and have a negative effect on several motor symptoms
including tremor, gait, dyskinesias, freezing, on/off fluctuations, and on
quality of life in general [1–3]. However, anxiety disorders in PD pa-
tients are often not recognized and consequently not treated [4, 5].
Neurobiological studies of affective processing have demonstrated
the involvement of an extensive frontal-subcortical limbic network [6],
which mainly depends on intact dopaminergic neurotransmission [7].
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PD is primarily characterized by the progressive degeneration of do-
paminergic systems and anxiety is believed to originate, at least in part,
from the underlying pathological process of PD [8, 9]. Indeed, anxiety
often appears prior to the appearance or recognition of motor symp-
toms [9], and even non-anxious PD patients already show altered
emotion regulation compared to healthy adults [10]. However, the fact
that anxiety symptoms do not reliably improve by L-DOPA replacement
therapy suggests that other mechanisms besides dopamine deficiency
are involved in the aetiology of anxiety symptoms in PD [11, 12], such
as the noradrenaline and serotonin systems. Both these systems are
implicated in affective processes and known to be substantially affected
in the PD process [13–15]. On the other hand, both fears and social
implications associated with motor symptoms of PD can provoke or
exacerbate anxiety symptoms in PD [16]. Given this complex interac-
tion between physiological and psychological factors and the diversity
of the disease, psychotherapeutic treatment of anxiety requires adap-
tations that are tailored to the specific needs of PD patients [17, 18].
Cognitive behavioural therapy (CBT) is considered the gold stan-
dard in psychotherapeutic treatment of anxiety in the general popula-
tion [19, 20]. CBT is defined as ‘An amalgam of behavioural and cognitive
problem-based interventions guided by principles of applied science. The
behavioural interventions aim to decrease maladaptive behaviours and in-
crease adaptive ones by modifying their antecedents and consequences and
by behavioural practices that result in new learning. The cognitive inter-
ventions aim to modify maladaptive cognitions, self-statements, or beliefs’
[21, 22]. In PD, CBT has been proven to be an effective treatment for
depression and impulse control disorders (ICD) [23–25]. PD patients
who received CBT for depression in a randomised controlled trial re-
ported not only a reduction in depression and comorbid anxiety, but
also a beneficial influence on coping and quality of life, compared to PD
patients who only received clinical monitoring [23]. To date, no clinical
trials specifically targeting anxiety in PD patients have been published.
However, there have been several pilot studies for CBT and internet-
based CBT in PD patients with mixed depressive and anxiety symptoms
or mild to moderate depression or anxiety symptoms, respectively
[25–27]. Both studies reported significant reductions in depressive
symptoms, but not in anxiety symptoms, which may have been due to
small sample sizes and lack of power [26, 27]. Another uncontrolled
study investigating the use of a tailored CBT module for anxiety in 12
PD patients showed that CBT can reduce anxiety levels with persisting
benefits at 3 and 6month follow-up [28]. Although the previous studies
are limited by their small sample size, and/or uncontrolled nature, they
warrant further exploration of CBT for anxiety in PD patients [25].
In addition to clinical effectiveness, several imaging studies have
demonstrated that psychotherapeutic interventions, including CBT, can
modify neural correlates of affective processing [29–32]. CBT-induced
increases in both functional [30, 33] and structural connectivity [34]
between limbic and frontal cortices have been demonstrated in patients
with social anxiety disorder (SAD), one of the most common anxiety
disorders in PD [1].
Here, we describe the design of the study Cognitive Behavioural
Therapy for Anxiety Disorders in Parkinson's Disease, a two-centre ran-
domised controlled trial (RCT) that aims to examine the clinical effec-
tiveness, cost-effectiveness as well as changes in cerebral connectivity
following CBT for anxiety in PD.
The main research questions are:
1) Is CBT treatment of anxiety in PD patients more effective than
clinical monitoring in terms of change in anxiety levels, quality of
life and well-being?
2) Is CBT treatment cost-effective, compared to clinical monitoring?
3) Does successful CBT treatment lead to changes in functional and
structural brain connectivity between the frontal and prefrontal
cortex and limbic structures such as the amygdala, cingulate gyrus
and hippocampus?
2. Methods
2.1. Study design
This study is a prospective, open RCT with PD patients recruited in
two centres in Europe (Maastricht University Medical Centre,
Maastricht, the Netherlands and Lille University Hospital, Lille,
France). Sixty PD patients with anxiety and their caregivers (optional)
will be randomised to CBT and clinical monitoring (intervention group)
or clinical monitoring only (control group). A randomised block design
with 6 blocks of 10 participants will be applied. All participants will
undergo standardised clinical, cognitive and behavioural assessment at
baseline (t=0), at the end of the intervention (t=1) as well as
3months after the intervention (t=2). Moreover, participants rando-
mised to the intervention group will receive an additional full assess-
ment at 6month follow-up (t=3). At baseline (t= 0) and at the end of
the intervention (t= 1) participants will undergo Magnetic Resonance
Imaging (MRI) scanning, except in case of contraindications for un-
dergoing MRI (e.g., deep brain stimulation, claustrophobia). The
duration of the intervention will be approximately 10–12weeks.
Participants randomised to the control group will be given the option to
receive CBT after the 3month follow-up assessment. This will be done
as clinical care and not be part of the study.
2.2. Study population
2.2.1. In- and exclusion criteria
Sixty patients with idiopathic PD according to the Queens Square
Brain Bank criteria [35] and their caregivers (optional) will be pro-
spectively enrolled. In- and exclusion criteria are listed in Table 1.
In order to achieve a representative study sample, participants will
be included irrespective of their disease stage or their current anti-
parkinsonian medication, provided a stable situation is present. In case
a caregiver is involved, the caregiver should have daily contact with the
Table 1
In- and exclusion criteria.
Inclusion criteria - Idiopathic PD according to the Queens Square Brain Bank diagnostic criteria [35]
- Presence of clinically relevant anxiety symptoms, as operationalized by a Parkinson Anxiety Scale (PAS) [3] persistent score > 9 and/or PAS avoidance
score > 3
- Using a stable dose of levodopa or other antiparkinsonian medication for at least 1 month
- No other current psychological treatment for anxiety; psychopharmacotherapy is allowed if a stable dose is used at least 2 months prior to participation
and the patient still meets inclusion criteria. During the trial the dosage should not be changed. Medication use and mental health care will be tracked
throughout the study.
- Age between 35 and 80 years old
Exclusion criteria - Parkinsonian syndromes or neurodegenerative disorders other than PD
- Dementia or severe cognitive decline, operationalized as a Montreal Cognitive Assessment (MoCa) [36] score < 24
- Major depressive disorder (MDD) as defined by the DSM 5 criteria [37]
- Abuse of alcohol, drugs or benzodiazepines
PD=Parkinson's disease, PAS=Parkinson Anxiety Scale, MoCa=Montreal Cognitive Assessment, MDD=Major Depressive Disorder; DSM 5=Diagnostic and
Statistical Manual of mental disorders, 5th edition.
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study participant and have no serious medical or psychiatric conditions.
2.2.2. Recruitment
Patients will be recruited from the Movement Disorders clinics in
the two participating centres. The treating neurologists will evaluate
initial eligibility of the patients. Moreover, flyers with general in-
formation about the study and contact details of the researchers will be
distributed in Movement Disorders clinics in other hospitals in the re-
gion and at several Parkinson support groups. After patients have been
informed about the study and agreed to participate, a baseline assess-
ment will take place, in which participants will be further screened to
evaluate whether they meet all in- and exclusion criteria. A flowchart of
the inclusion procedure is presented in Fig. 1.
2.2.3. Randomisation, blinding and treatment allocation
After informed consent is obtained and the baseline measurement is
performed, participants will be randomly assigned to one of two groups:
the intervention group or control group. Randomisation will be per-
formed over both centres together in order to compensate for between-
centre differences in population and involves a randomised block de-
sign with 6 blocks of 10 participants. Randomisation is performed by
the coordinating investigator using the website randomization.com.
Assessments will be performed by a psychologist who is not involved
with the treatment and blinded for the intervention. The participants
will be instructed not to comment on the intervention they received.
2.3. Intervention
2.3.1. CBT Treatment
Participants randomised to the intervention group will receive CBT
and clinical monitoring. The CBT consists of 10 weekly individual
sessions of 60–75min, tailored to the preferences and needs of each
patient. In each session, a registered psychologist will address specified
aspects of (coping with) anxiety and related concerns with a specific
focus on behaviour and thoughts associated with anxiety. Any other
neuropsychiatric symptoms that are present, such as depressive symp-
toms or apathy, will be addressed as well, although the main focus will
be on anxiety.
The content of the CBT module was based on existing literature of
CBT treatment of GAD and SAD and on published existing modules for
CBT in anxiety and depression. Published existing modules include
amongst others: psycho-education and awareness, motivational inter-
viewing, behaviour activation, thought monitoring and restructuring,
exposure, relaxation techniques, coping and problem solving skills,
exercise, and sleep hygiene [23, 26, 38–40]. We adjusted these existing
modules to better serve the specific needs, concerns, and circumstances
of PD patients with anxiety. The resulting module was subsequently
presented to small groups of PD patients and their caregivers (in ‘focus-
groups’), as well as to representatives of the scientific section of the
Dutch Parkinson Patient Foundation (Parkinsonpatiëntenvereninging)
and to PD experts in both countries, in order to gather patient and
professional feedback, respectively. The final CBT module, which con-
sists of a treatment manual for therapists and a workbook for patients,
was originally written in English and later translated to French and
Dutch.
All CBT sessions have a similar overall structure. Each session will
start with setting the agenda for that particular session, after which the
home assignments will be reviewed (in all but the first session). Then
the new topic will be introduced and exercises related to the new topic
will be practiced. Subsequently, the new home assignments for the
upcoming week will be discussed as well as possible barriers or con-
cerns for completing the new tasks and/or tasks from previous sessions.
Fig. 1. Study flow chart.
A.E.P. Mulders et al. Journal of Psychosomatic Research 112 (2018) 32–39
34
The first and last session will have some additional components related
to the introduction and termination of the therapy, respectively. An
overview of the sessions is provided in Table 2.
Home assignments are an important part of CBT. In order to over-
ride dysfunctional patterns that promote anxiety and achieve change,
repeated practice in daily life is necessary. Patients will receive a
workbook during the first session. Each week the workbook will be
supplemented with handouts and worksheets that correspond to the
current topic. Even though patients with severe cognitive impairment
(MoCa score < 24) will be excluded from participation, cognitive
problems are common in PD patients [41], and probably a substantial
proportion of the participants will experience cognitive problems to
some degree. These usually relate to deficits in attention and executive
function, although memory deficits and visuospatial functions are also
frequent [42]. Therefore, all sessions and accompanying handouts and
worksheets have a clear structure and the psychologist will always
check whether the information and assignments are clear to the parti-
cipant and whether there are any barriers or concerns for completing
the home assignments. If necessary, the psychologists will problem-
solve any issues. The therapy sessions will take place at the outpatients
of the Movement Disorders Clinics of the two participating centres. In
case medical or other reasons make it difficult for the patient to visit the
clinics, the treating therapist can visit the participants at home.
2.3.2. Clinical monitoring
Clinical monitoring has been recommended as a control situation
when exploring the clinical effectiveness of a new or adjusted psy-
chotherapeutic intervention [43]. All patients will receive clinical
monitoring; those not randomised to the intervention group will receive
clinical monitoring only. Clinical monitoring involves a phone call by
an independent psychologist one month following the baseline assess-
ment to inquire about current anxiety symptoms. Moreover, partici-
pants will receive general education material on coping with anxiety,
derived from the Dutch/French psychiatric association webpages. Par-
ticipants in the control group will remain under the care of their per-
sonal physicians, who will also monitor their medical and psychiatric
status. During the intervention and follow-up period, all participants
are asked to give notice when starting with any other form of psy-
chotherapeutic interventions or psychopharmacotherapy for their an-
xiety. Those patients randomised to the control condition of clinical
monitoring only, will be given the opportunity to receive CBT after the
3month follow-up assessment. This treatment will be part of regular
patient care and is covered by the patient's health insurance. Hence, it
will not be part of the study.
2.4. Outcome measures
The primary outcome for studying the clinical effectiveness of the
CBT treatment is the difference between the intervention and control
group in anxiety score changes between baseline (t=0) and post-
treatment (t=1) as measured with the Hamilton Anxiety Rating Scale
(HARS) [44]. Secondary outcome measures involve long-term clinical
effectiveness, which will be assessed similarly, but then using the 3-
month (t=2) and 6-month follow-up anxiety scores (t=3, interven-
tion group only). Moreover, changes in functional and structural cere-
bral connectivity between the frontal and prefrontal cortex and limbic
structures such as the amygdala, cingulate gyrus and hippocampus
before and after the intervention will be studied, as measured with
resting-state MRI (rs-fMRI) and Diffusion Tensor Imaging (DTI). The
difference in effectiveness between CBT and clinical monitoring in
terms of disease-specific quality of life, generic health-related quality of
life and well-being will be assessed using the Parkinson's Disease
Questionnaire-8 (PDQ-8) [45], the EQ-5D-5 L [46] and Icepop Cap-
ability measure for older people (ICECAP-O) [47], respectively. Lastly,
care resource utilization will be obtained by an adapted version of the
Resource Utilisation in Dementia [48] questionnaire. Other study
parameters involve changes in comorbid psychiatric symptoms, motor
symptoms, sleep disturbance, coping, as well as caregiver burden. An
overview of all questionnaires is provided in Table 3.
The demographic and disease-related variables that will be collected
during baseline include sex, date of birth, years of formal education,
year of PD onset, side of onset, year of PD diagnosis, details on
Parkinson medication (i.e., drug name, dose, frequency, levodopa
equivalence) and other medication including psychopharmacology, al-
cohol use, medical history (i.e., cerebrovascular diseases, psychiatric
disorders) and family medical history (i.e., PD, other neurological dis-
orders, dementia, psychiatric disorders). Any change in Parkinson
medication will be tracked during the whole study period.
2.4.1. MRI scan
MRI will be acquired using a 3 T whole-body scanner (Achieva TX,
Table 2
Overview of the cognitive behavioural therapy sessionsa.
Session
1 Introduction and psycho-education about anxiety
2 Monitoring anxiety
3 Management of anxiety: introduction and the importance of self-
management
4 Management of anxiety: diaphragmatic breathing and mindful awareness
5 Changing thoughts
6 Management of anxiety: progressive muscle relaxation and imagery
7 Problem solving
8 Changing anxiety behaviour
9 Review session
10 Self-management plan and closure
Booster sessionb
a A detailed treatment protocol and therapist manual have been developed.
Moreover, participants will receive a workbook with handouts and worksheets.
b Each patient will receive a booster session 1.5 month following the final
treatment session. The aim of the booster session is the monitor the patient's
progress, to provide clinical assistance if necessary, and to encourage continued
use of coping skills.
Table 3
Questionnaires administered at t=0, t=1, t= 2 and t=3a.
Instrument
Anxiety Hamilton Anxiety Rating Scale [44]
Parkinson Anxiety Scale [3]
Liebowitz Social Anxiety Scale [49]
Mini International Neuropsychiatric
Inventory section G and O [50]
Global cognitive status Montreal Cognitive Assessment [36]
Depression Hamilton Depression Rating Scale [51]
Apathy Lille Apathy Rating Scale [52]
Health-related quality of life Parkinson's Disease Questionnaire [45]
EQ-5D-5Lb [46]
Well-being ICECAP-Ob [47]
Sleep and nocturnal disturbances Parkinson's Disease Sleep Scale 2 [53]
Coping strategies Brief Cope scale [54], Thought Control
Questionnaire [55]
Health-related costs, patient and
family related costs
Adapted version of the Resource Utilisation
in Dementiac [48]
Motor symptom severity MDS-UPDRS [56]
PD disease stage Hoehn & Yahr staging [56]
Caregiver burden Zarit burden interview [57]
EQ-5D-5 L=Euroqol quality of life scale - 5 dimensions - 5 levels, ICECAP-
O= Icepop Capability measure for older people, MDS-UPDRS=Movement
Disorder Society – Unified Parkinson's Disease Rating Scale.
a t= 0: baseline measurement, t= 1: post-intervention measurement, t=2:
3-month follow up, t= 3: 6-month follow-up for intervention group only.
b Will be administered to both participants and caregivers.
c In this version the formulation of items has been adjusted to Parkinson's
disease instead of dementia and two questions regarding use of speech therapy
and home aids were added.
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Philips Healthcare, Best, the Netherlands) using a 32-channel head coil
for signal reception. The MRI protocol includes an anatomical scan, rs-
fMRI, DTI and B0 field map. The total MRI scan will take about 45min.
Details of the brain MRI protocol can be found in Table 4. Imaging will
be performed at the Department of Radiology of Maastricht University
Medical Centre and at the Department of Radiology of Lille University
Hospital.
2.4.2. Data collection and management
All personnel involved in the data collection will review the stan-
dard operating procedures (SOP) and manuals. Assessors are certified in
Good Clinical Practice (GCP) and in performing the MDS-UPDRS part III
[56]. Data will be collected on paper forms and entered into a web-
based data entry portal of which a back-up will be stored electronically
on a daily basis. The data of all participants will be handled con-
fidentially. A subject identification code list will be used to trace data to
an individual subject. The coordinating investigator will provide all
data of subjects with a number that is not based on the patient's initials
and birth-date. The key to the code will be safeguarded by the co-
ordinating investigator. All data will be stored for 15 years as required
by law.
2.4.3. Power and sample size calculation
Power calculation was based on a standardised difference of 0.8 in
HARS total score, with alpha set at 0.05 and power set at 0.80, and a
predicted effect size of Cohen's d (0.95), based on a previous RCT with
CBT in PD [23]. The standardised difference is defined as the ratio of
the difference of interest to the standard deviation in scores of the
sample. The difference of interest was set 3 points on the HARS (being
the difference in average scores between patients without anxiety and
with mild anxiety [2]; standard deviation was estimated at 5 [2, 23].
Based on these quantities, the required number of patients to be in-
cluded is 40 (20 per group). Including 30 patients per group would
allow for a drop-out of approximately 30%. This is a conservative
sample size calculation since, based on the only published RCT of CBT
in depression in PD [23], we expect that the effect size will be larger
(> 5 points) and drop-out will be lower (< 10%). If subjects decide to
leave the study prematurely they will not be replaced by new partici-
pants. The dropped out participants will be included in the analysis
according to the intention-to-treat principle (ITT).
No sample size calculation was made for the MRI analyses specifi-
cally, since longitudinal data to determine the sensitivity of different
DTI parameters to change over time are lacking. However, taking the
sample size of published studies in this area as reference [32, 34, 58,
59], we expect to be overpowered for these analyses using the same
sample size as for the analysis of clinical efficacy.
2.5. Statistical analyses
Unless indicated otherwise, analysis will be performed using IBM
SPSS statistics 24.0, Stata 13, or more recent versions if available.
Significance level of 0.05 will be used. The numerical variables will be
described as means, median, standard deviations and ranges.
Categorical variables will be described as frequencies and percentages.
Data analyses of primary and secondary outcomes will be conducted
using relevant univariate, multivariate and multilevel techniques. For
the primary study parameter, between-group comparisons will be
conducted on post-treatment data and 3month follow-up data in order
to compare within-subject changes in anxiety scores (HARS) relative to
baseline between the intervention and control group. This will be done
using separate repeated measures Analysis of Covariance (rm-ANCOVA)
for each of the two outcomes. Covariates include the use of benzodia-
zepines and antidepressants, Parkinson medication, which will be
converted into levodopa equivalents using the algorithm of Tomlinson
et al. [60], as well as significant differences in other relevant para-
meters. For the secondary parameters, between-group comparisons will
be likewise conducted on post-treatment data and 3month follow-up
data to assess differences in changes relative to baseline between the
intervention- and control group. To compare changes in anxiety scores
and the secondary parameters between baseline and 6month follow-up
in the intervention group, within-subject comparisons will be per-
formed.
For MRI scan analyses, between-group analyses using paired-sample
and two-sample t-tests will be conducted to calculate differences in
changes in cerebral connectivity pre- and post-intervention. Functional
connectivity measures and graph topology indices will be extracted
from rs-fMRI data [61]. Diffusion metrics (fractional anisotropy, radial
and axial diffusivity) and structural connectivity computed from DTI
data will be also used as descriptive variables in the statistical com-
parisons [62].
The economic evaluation will be performed following the Dutch
guideline for economic evaluations in healthcare. The incremental cost-
effectiveness ratio (ICER) will be calculated using standard unit price
based costs in combination with the adapted RUD and EQ-5D-5 L utility
based QALYs. An ITT analysis, a 3-month time horizon and a societal
perspective will be adopted. A bootstrap analysis will be used to reflect
the uncertainty in this ICER.
3. Drop-outs, missing values and adverse events
Participants can leave the study at any time for any reason or no
reason at all if they wish to do so without any consequences. The in-
vestigator can decide to withdraw a subject from the study for urgent
medical reasons. If subjects decide to leave the study prematurely they
will not be replaced by new participants. The dropped out participants
will be included in the analysis according to the ITT. For the ITT ana-
lyses, missing values on the primary outcome will be imputed using
multiple imputations. For this, ten imputed datasets will be generated
using multivariate multiple imputation by chained equations (MICE)
[63] with demographic, clinical and baseline values of the primary
outcome as predictors of the missing outcome values as well as vari-
ables predicting missingness (e.g. age, illness severity, morbidity). This
technique yields better (i.e. less biased) estimates for outcome analyses
in RCTs than single imputation or complete case analysis with covariate
adjustment for missingness, especially if data are not-missing-at-
random (i.e. missingness is related to unobserved variables) [64].
Subsequent analyses on imputed datasets will be performed in state 13
or higher [65].
Adverse events are defined as any undesirable experience occurring
Table 4
Brain MRI scanning protocol.
Sequences 3D T1-weighted MP-
RAGE
Resting-
state fMRI
Diffusion
tensor
imaging
(DTI)
B0 Field map
Field of view
(mm)
240×240 192×192 256×256 256×256
Matrix 256× 256 64×64 128×128 128×128
Slices 231 40 66 66
Inter-
slicegap
(mm)
0 0 0 0
Voxel (mm3) 0.65×0.65× 0.65 3x3x3 2x2x2 2x2x2
TR/TE (ms) 12/3.3 2400/30 12,000/56 660/4
Flip angle 9° 90° 90° 80°
B value (ms/
mm2)
1000
Nr of
direc-
tions
32
MP RAGE=magnetization-prepared 180° radio-frequency pulses and rapid
gradient-echo, fMRI= functional Magnetic Resonance Imaging.
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to a subject during the study, which may or may not be related to the
trial procedure or experimental intervention. All spontaneously re-
ported study-related adverse events by the subject or observed by the
investigator or his staff will be recorded according to section 10, sub-
section 1 of the Dutch Research Involving Human Subjects Act (WMO).
In case of a serious adverse event the sponsor, the Ethics committee and
other relevant authorities such as the principal investigator and Toet-
singonline will be notified immediately. A liability insurance which is
in accordance with the legal requirements in the Netherlands (Article 7
WMO) and France has been signed.
3.1. Medication adjustments
Preferably, Parkinson medication is kept stable during the study.
Nonetheless, if medication changes are presumed necessary by the
treating neurologist, they are allowed to do so. Any changes in medi-
cation will be tracked during the intervention period and follow-up
moments. Psychopharmacotherapy is allowed if, by the start of the
study, a stable dose is used at least 2 months prior to participation and
the patient still meets the inclusion criteria.
3.2. Ethical approval, trial registration and monitoring
The study is carried out in compliance with the Helsinki
Declaration. The local ethics committee of Maastricht University
Medical Centre (July 2016) and Lille University Hospital (September
2016) have approved the study protocol. Written informed consents
will be obtained from all participants. The study is registered at the
ClinicalTrials.gov database under registration number NCT02648737,
as well at FoxTrialFinder under ID number 004701. The study will be
monitored in both centres by Clinical Trial Center Maastricht according
to the international ICH-GCP guidelines.
4. Discussion
The overall aim of this open, two-centre RCT is to evaluate the
clinical effectiveness of a CBT module for the treatment of anxiety in
patients with PD and provide additional information on cost-effective-
ness and the underlying changes in functional and structural brain
connectivity that occur during this treatment. The treatment module is
specifically designed to serve the needs, concerns, and circumstances of
PD patients with anxiety and is based on the knowledge and experience
of PD experts. CBT will, if proven effective, provide PD patients with
behavioural and anxiety management techniques that may give lasting
benefits on anxiety symptoms, well-being, quality of life, and possibly
on motor symptoms. In this multinational RCT design patients are re-
cruited in two countries at both outpatient clinics and informal meeting
points for PD patients. This way of recruiting facilitates generalizability,
as a broader range of patients can be reached instead of solely patients
with more severe PD symptoms that come from the Movement
Disorders Clinics.
While most studies investigating brain alterations following psy-
chotherapeutic interventions use functional imaging methods, only few
have examined structural brain correlates of CBT [30, 31, 34]. One
study using structural and diffusion MRI measures observed reductions
in parieto-occipital and prefrontal gray matter volumes, increases in
fractional anisotropy in two anxiety-related white matter fiber tracts, as
well as increases in structural connectivity in a frontolimbic network
following a 10-week group-based CBT protocol for SAD patients [34].
Albeit in the absence of a control group and in a different patient po-
pulation, this study provided insight into how the brain adapts to
psychotherapeutic treatments. Our study is the first one that aims at
assessing both functional and structural brain alterations following CBT
in PD patients using different MRI modalities, such as rs-MRI and DTI,
in the presence of a control group. Therefore, this study has an addi-
tional value to earlier CBT trials in PD patients [23, 26, 28], as it may
provide increased understanding of the underlying biological mechan-
isms of both anxiety and response to treatment in PD patients. More-
over, it can provide additional insight into whether CBT effects differ
between different anxiety disorders and patient populations.
There are, however, also some limitations in this study design.
Firstly, the follow-up duration of 3months is relatively short to evaluate
the long-term benefits of the CBT treatment. However, we agreed it was
ethically not acceptable to deny the control group CBT treatment for a
period longer than 6months following the start of the intervention.
Alternatively, we added an additional follow-up moment (t=3) for
patients randomised to the intervention group 6months after the CBT
treatment, which will give the possibility to study within-subject
changes over time and provide insight into long-term benefits of the
CBT treatment. Secondly, although there are no major risks associated
with participation in the CBT intervention, participating in the study
can be time-consuming and demanding for participants, especially
considering the relatively high health care utilization in PD patients.
Some PD patients might not be able to travel independently and have to
rely on others, such as partners, family members, friends or other
caregivers. These factors make inclusion and treatment adherence
challenging. We discussed the feasibility of the number of sessions in
multiple PD focus groups and none of the participants, neither in the
Netherlands nor in France, perceived the frequency of the sessions as
too burdensome or as a reason not to participate. In case medical or
other practical reasons hinder participants to visit the outpatient clinic,
the therapist can visit the participant at the site where the participant
resides. We do not expect this to influence the treatment. Thirdly, with
the involvement of different therapists, there is a risk of therapist ef-
fects, which refers to the tendency of different therapist to obtain dif-
ferential symptomatic change in the patients [66]. However, all of our
therapists have received appropriate training, and a detailed treatment
protocol and therapist manual have been developed, which has shown
to minimize therapist effects [67, 68]. Despite our efforts to standardise
the intervention as much as possible, the involvement of a caregiver
during the CBT intervention might likewise moderate treatment out-
come as it is optional and not necessary for participation in the study.
The purpose of their attendance is primarily to offer caregivers the
opportunity to learn about the treatment in which the participant is
involved and to explore strategies through which they can support the
participant if necessary. This can vary from motivating the participant
to do the home assignments up to assisting them to fill out the work-
sheets in case physical reasons make this difficult. The caregiver at-
tendance is limited to three educational sessions.
In conclusion, this low risk intervention study has great relevance
for clinical practice. It evaluates the clinical effectiveness of a CBT
module for anxiety in PD and contributes to a better understanding of
the underlying biological mechanisms of anxiety in PD. Inclusion
started March 2017 and we aim to complete the study in 2019.
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